8-K filing — LABCORP HOLDINGS INC. (LH)
Filed: 2026-10-28 AccNo: 0000920148-26-000213 Size: 736 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Labcorp announced its third-quarter 2026 financial results, reporting a 7% year-over-year revenue increase and raising its full-year 2026 guidance.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-28 AccNo: 0000920148-26-000213 Size: 736 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Labcorp has entered into a partnership with Waters Corporation to offer the FDA-approved BD Onclarity HPV Assay across its U.S. laboratory network starting in late 2026.
Labcorp has entered into a collaborative partnership with Charles River Laboratories and the FDA to conduct research on the potential abuse of medicines.